Congenital malformations of newborn infants after clomiphene-induced ovulation

Fertility and Sterility, 40(2), 187-189

DOI 10.1016/s0015-0282(16)47235-3 PMID 6873315

Abstract

The effect of clomiphene citrate (CC) on the incidence of congenital malformations in newborn infants was assessed from the outcome of 1034 pregnancies after CC-induced ovulation recorded at nine university hospitals in a 5-year period. Of these pregnancies, 14.2% ended in abortion, 0.5% in ectopic pregnancy, 0.1% in molar pregnancy, and 1.6% in stillbirth. In all, 935 infants were born, and 21 (2.3%) showed visible malformations. This incidence of malformations was not significantly different from that in 30,033 infants (1.7%) after spontaneous ovulation (spontaneous ovulation group), and the types of malformations after CC treatment were similar to e those in the spontaneous ovulation group. These data indicate that CC has no teratogenic effect.

Topics

clomiphene citrate congenital malformations newborn teratogenic effect, clomiphene induced ovulation birth defects pregnancy outcome, Kurachi Aono clomiphene citrate malformation incidence, clomiphene ovulation induction fetal safety congenital anomalies, CC treatment pregnancy outcome abortion ectopic stillbirth rate, clomiphene citrate teratogenicity large cohort study Japan, ovulation induction drug safety newborn malformation rate, clomiphene versus spontaneous ovulation congenital malformation comparison, fertility drug clomiphene pregnancy outcome birth defect risk, clomiphene citrate 1034 pregnancies multicenter study malformations
PMID 6873315 6873315 DOI 10.1016/s0015-0282(16)47235-3 10.1016/s0015-0282(16)47235-3

Cite this article

Kurachi, K., Aono, T., Minagawa, J., & Miyake, A. (1983). Congenital malformations of newborn infants after clomiphene-induced ovulation. *Fertility and sterility*, *40*(2), 187-189. https://doi.org/10.1016/s0015-0282(16)47235-3

Related articles